Recursion Pharmaceuticals Inc (RXRX)
6.89
-0.04
(-0.58%)
USD |
NASDAQ |
Nov 08, 11:00
Recursion Pharmaceuticals Revenue (TTM): 64.60M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 64.60M |
| June 30, 2024 | 48.62M |
| March 31, 2024 | 45.23M |
| December 31, 2023 | 43.88M |
| September 30, 2023 | 46.93M |
| June 30, 2023 | 49.88M |
| March 31, 2023 | 46.52M |
| Date | Value |
|---|---|
| December 31, 2022 | 39.68M |
| September 30, 2022 | 28.50M |
| June 30, 2022 | 17.95M |
| March 31, 2022 | 12.80M |
| December 31, 2021 | 10.00M |
| September 30, 2021 | 10.05M |
| June 30, 2021 | 8.413M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
8.413M
Minimum
Jun 2021
64.60M
Maximum
Sep 2024
33.79M
Average
41.78M
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Pfizer Inc | 59.37B |
| Revance Therapeutics Inc | 243.90M |
| Twist Bioscience Corp | 295.21M |
| NovaBay Pharmaceuticals Inc | 12.02M |